PHARMACEUTICAL COMPOSITIONS COMPRISING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION
The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) a suspension of particles comprising 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) a diluent which is 1,1,1,2-tetrafluoroethane (HFA-134a), wherein the liquid pharmaceutical composition is substantially free of surfactant. The invention also relates to a pressurised metered dose inhaler comprising the liquid pharmaceutical composition.
1 . A method of treating chronic obstructive pulmonary disease (COPD) or asthma in a subject, which method comprises administering to said subject an effective amount of a liquid pharmaceutical composition, which liquid pharmaceutical composition is suitable for administration by inhalation and comprises:
(i) a suspension of particles comprising 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4- one (RPL554); and
(ii) a diluent which is 1,1,1,2-tetrafluoroethane (HFA-134a), wherein the liquid pharmaceutical composition comprises less than 0.05% by weight of a surfactant relative to the total weight of the composition.
2 . The method according to claim 1 , wherein the liquid pharmaceutical composition contains less than 0.05% by weight of any additional excipient selected from a co-solvent and a surfactant relative to the total weight of the composition.
3 . The method according to claim 1 , wherein the liquid pharmaceutical composition contains less than 0.05% by weight of any additional excipient relative to the total weight of the composition.
4 . The method according to claim 1 , wherein the liquid pharmaceutical composition contains less than 0.01% by weight of said surfactant, relative to the total weight of the composition.
5 . The method according to claim 1 , wherein the particles comprise at least 50% by weight of RPL554 relative to the total weight of the particles.
6 . The method according to claim 1 , wherein RPL554 is the sole active agent in the liquid pharmaceutical composition.
7 . The method according to claim 1 , wherein the liquid pharmaceutical composition consists essentially of (i) RPL554 and (ii) 1,1,1,2-tetrafluoroethane.
8 . The method according to claim 1 , wherein the liquid pharmaceutical composition comprises at least 99.5% by weight of (i) RPL554 and (ii) 1,1,1,2-tetrafluoroethane relative to the total weight of the composition.
9 . The method according to claim 1 , wherein the particles comprising RPL554 have a particle size distribution with a Dv50 (median particle size by volume) value of from about 0.2 μm to about 5 μm.
10 . The method according to claim 1 , wherein the concentration of particles comprising RPL554 in the liquid pharmaceutical composition is from about 5.0 mg/mL to about 200 mg/mL.
11 . The method according to claim 1 , wherein the liquid pharmaceutical composition is suitable for administration by pressurised metered dose inhaler.
12 . The method according to claim 1 , wherein the liquid pharmaceutical composition is administered by a pressurised metered dose inhaler comprising.
13 . (canceled)
14 . The method according to claim 1 , wherein the asthma is selected from allergic asthma, steroid resistant asthma, severe asthma, and paediatric asthma.
15 . The method according to claim 1 , wherein the method is a method of treating chronic obstructive pulmonary disease (COPD).
16 . (canceled)
17 . The method according to claim 2 , wherein the liquid pharmaceutical composition contains less than 0.01% by weight of said excipient, relative to the total weight of the composition.
18 . The method according to claim 1 , wherein the liquid pharmaceutical composition contains less than 0.001% by weight of said surfactant, relative to the total weight of the composition.
19 . The method according to claim 2 , wherein the liquid pharmaceutical composition contains less than 0.001% by weight of said additional excipient, relative to the total weight of the composition.
20 . The method according to claim 1 , wherein the particles comprise at least 99% by weight of RPL554 relative to the total weight of the particles.
21 . The method according to claim 1 , wherein the concentration of RPL554 in the liquid pharmaceutical formulation is such that the dose of RPL554 delivered per actuation of an inhaler comprising the liquid pharmaceutical composition is from 500 μg/actuation to 1500 μg/actuation.